GSK Raises 2025 Outlook on Strong HIV and Cancer Drug Sales
British pharmaceutical giant GSK has lifted its full-year 2025 guidance after a strong third quarter. Sales jumped thanks to double-digit growth in its HIV and cancer drug portfolios. The company reported Q3 revenue of about £8.55 billion, beating market expectations. Core earnings per share reached 55 pence, up significantly from the same quarter last year. …